Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Melanoma 11Breast Neoplasms 3Triple Negative Breast Neoplasms 2Sarcoma 2Pancreatic Neoplasms 2Carcinoma, Merkel Cell 2Squamous Cell Carcinoma of Head and Neck 1Peritoneal Neoplasms 1Neoplasm Metastasis 1Lymphoma, T-Cell, Cutaneous 1Colorectal Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Hepatocellular 1Carcinoma, Ductal, Breast 1Carcinoma, Ductal 1Carcinoma, Basal Cell 1Advanced Non CNS Tumors 1Adenocarcinoma 1

Interventions

Gemcitabine 27Fluorouracil 25Oxaliplatin 21Cisplatin 19Leucovorin 17Bevacizumab 15130-nm albumin-bound paclitaxel 13Docetaxel 12Capecitabine 12Albumin-Bound Paclitaxel 12Paclitaxel 11Irinotecan 10Carboplatin 9pembrolizumab 7Radiotherapy 6Pemetrexed 6Nivolumab 6Erlotinib Hydrochloride 6Cyclophosphamide 6Trastuzumab 5Ramucirumab 5Ipilimumab 4Everolimus 4Crizotinib 4Cetuximab 4vandetanib 3trastuzumab deruxtecan 3sargramostim 3folfirinox 3Sorafenib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Adenocarcinoma × talimogene laherparepvec × Clear all
NCT00402025 2016-04-15

Talimogene Laherparepvec in Patients With Unresectable Pancreatic Cancer

BioVex Limited

Phase 1 Completed
17 enrolled 14 charts
Gastrointestinal

Adenocarcinoma, Neoplasm Metastasis, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡